Buckle Tessa, van Alphen Maarten, van Oosterom Matthias N, van Beurden Florian, Heimburger Nina, van der Wal Jaqueline E, van den Brekel Michiel, van Leeuwen Fijs W B, Karakullukcu Baris
Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Cancers (Basel). 2021 May 28;13(11):2674. doi: 10.3390/cancers13112674.
Intraoperative tumor identification (extension/margins/metastases) via receptor-specific targeting is one of the ultimate promises of fluorescence-guided surgery. The translation of fluorescent tracers that enable tumor visualization forms a critical component in the realization of this approach. Ex vivo assessment of surgical specimens after topical tracer application could help provide an intermediate step between preclinical evaluation and first-in-human trials. Here, the suitability of the c-Met receptor as a potential surgical target in oral cavity cancer was explored via topical ex vivo application of the fluorescent tracer EMI-137. Freshly excised tumor specimens obtained from ten patients with squamous cell carcinoma of the tongue were incubated with EMI-137 and imaged with a clinical-grade Cy5 prototype fluorescence camera. In-house developed image processing software allowed video-rate assessment of the tumor-to-background ratio (TBR). Fluorescence imaging results were related to standard pathological evaluation and c-MET immunohistochemistry. After incubation with EMI-137, 9/10 tumors were fluorescently illuminated. Immunohistochemistry revealed c-Met expression in all ten specimens. Non-visualization could be linked to a more deeply situated lesion. Tumor assessment was improved via video representation of the TBR (median TBR: 2.5 (range 1.8-3.1)). Ex vivo evaluation of tumor specimens suggests that c-Met is a possible candidate for fluorescence-guided surgery in oral cavity cancer.
通过受体特异性靶向进行术中肿瘤识别(范围/切缘/转移情况)是荧光引导手术的最终目标之一。能够实现肿瘤可视化的荧光示踪剂的转化是实现该方法的关键组成部分。局部应用示踪剂后对手术标本进行体外评估有助于在临床前评估和首次人体试验之间提供一个中间步骤。在此,通过荧光示踪剂EMI-137的局部体外应用,探讨了c-Met受体作为口腔癌潜在手术靶点的适用性。从10例舌鳞状细胞癌患者获取的新鲜切除肿瘤标本与EMI-137孵育,并用临床级Cy5原型荧光相机成像。自行开发的图像处理软件允许以视频速率评估肿瘤与背景的比率(TBR)。荧光成像结果与标准病理评估和c-MET免疫组织化学相关。与EMI-137孵育后,10个肿瘤中有9个被荧光照亮。免疫组织化学显示所有10个标本中均有c-Met表达。未能观察到荧光可能与病变位置较深有关。通过TBR的视频呈现改善了肿瘤评估(TBR中位数:2.5(范围1.8 - 3.1))。肿瘤标本的体外评估表明,c-Met是口腔癌荧光引导手术的一个可能候选靶点。